Suvretta Capital Management, LLC has demonstrated a strong buying bias in its recent insider transactions, exclusively acquiring shares without any sales activity across its holdings. According to SEC Form 4 filings, the firm executed 35 purchases totaling $44.7 million, all concentrated in two biotech companies: MANE and BNTC. The bulk of its recent activity has focused on MANE, with 25 purchases between February 4 and February 6, 2026, ranging from $58,910 to nearly $1.98 million per transaction. Notably, the largest single purchase occurred on February 4, 2026, when Surovretta acquired MANE shares worth $1.98 million, followed by another sizable $986,836 investment the same day. Earlier, in late December 2025, the firm also accumulated BNTC shares in multiple transactions, including an $884,352 purchase on December 29 and a $547,410 acquisition on December 23. The absence of any sell-side activity suggests a sustained accumulation strategy, particularly in MANE, where recent trades account for the majority of the firm’s disclosed transactions. The pattern reflects a concentrated, buy-heavy approach in the biotech sector, with no diversification into other industries or profit-taking moves in the reported period.
AI-assisted summary